Method for delaying muscle atrophy after mouse denervating by using miR-143 inhibitor

Abstract

The invention relates to a method for delaying muscle atrophy after mouse denervating by using a miR-143 inhibitor. The method is characterized in that a microRNA-143 (miR-143) inhibitor is injected into a part with muscle atrophy, so as to delay the muscle atrophy process after denervating. The method comprises the following steps of firstly performing sciatic nerve axotomy on a mouse, building a mouse gastrocnemius muscle denervating atrophy model, quantitatively detecting the expression amount of miR-143 via PCR (polymerase chain reaction) in real time, and comparing the wet weight of gastrocnemius muscle and the diameter of muscle fiber; injecting the miR-143 inhibitor into the part with muscle atrophy, so that the expression amount of the mir-143 in the mouse gastrocnemius muscle is obviously reduced, and the diameter of the tissue muscle fiber of the mouse denervating gastrocnemius muscle injected with 10nmol of the miR-143 inhibitor is obviously higher than the diameter of a contrast group. The method has the advantage that the expression amount of the miR-143 in the mouse gastrocnemius muscle is reduced by injecting the miR-143 inhibitor, so that the muscle atrophy process of the mouse denervating gastrocnemius muscle is delayed.

Description

technical field [0001] The invention belongs to the cell and tissue engineering technology in the field of biotechnology, and specifically relates to a method for delaying muscle atrophy after denervation in mice by using miR-143 inhibitors. Background technique [0002] Skeletal muscle is the target organ of the peripheral nervous system. Peripheral nerves have the function of controlling muscle movement and contraction. The growth, development and normal function maintenance of muscles depend on the control and regulation of motor nerves. After the peripheral nervous system is injured, because the neurons no longer transport nutrients to the corresponding skeletal muscle fibers through the axoplasm, the skeletal muscles lose their innervation, motor contraction function, and gradually atrophy. Denervated muscle atrophy is a complex process, and the expression of various proteins and genes will change after nerve injury. After peripheral nerve injury, skeletal muscles will...

AI Technical Summary

Problems solved by technology

[0004] At present, there have been research reports on the treatment of muscle injury by regulating the expression of miRNA, but the number is small, and the types of miRNA targeted and the specific type of injury are also different. Through searching, we retrieved the authorized announcement number: 101448942B, and the name is: Invention patent related to MICRORNA that regulates muscle cell proliferation and differentiation. According to the relevant research results of cell proliferation and differentiation, this patent proposes a method for regulating the expression level of miRNA in vivo to treat muscle damage. In the embodiment, this patent combines miR-133 and miR -1 or a combination of their inhibitors are given to the muscle injury site to improve the recovery of muscle injury. Although the patent mentioned miR-143 in the selection of targeting miRNA, it did not verify the use method and effect of miR-143 , In addition, the type of muscle injury targeted by this patent is mechanical muscle injury and muscle tissue degenerative disease (muscular dystrophy or neuron disease, etc.), and does not analyze the case of denervated muscle atrophy

In the preliminary study of the patent of the present invention, we found that miR-143 has a regulatory effect on the in vitro proliferation and differentiation of skeletal muscle satellite cells (the aforementioned patent does not have a research basis for miR-143 to regulate skeletal muscle satellite cells), miR-143 in Whether in vivo has a certain regulatory effect on muscle injury repair is not clear

Images